21 filings
8-K
Neogenix Oncology Inc
28 Sep 12
Entry into a Material Definitive Agreement
12:00am
8-K
Neogenix Oncology Inc
7 Sep 12
Entry into a Material Definitive Agreement
12:00am
8-K
Neogenix Oncology Inc
26 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
Neogenix Oncology Inc
6 Jul 12
Departure of Directors or Certain Officers
12:00am
8-K
Neogenix Oncology Inc
3 Jul 12
Other Events
12:00am
8-K
78gblkw
6 Mar 12
Other Events
12:00am
8-K
l25iyn3q66qepzg0
6 Feb 12
Departure of Directors or Certain Officers
12:00am
8-K/A
d71t6jl
12 Jan 12
Departure of Directors or Certain Officers
12:00am
8-K
9zgjom 94sa2e8ui
12 Jan 12
Other Events
12:00am
8-K/A
kk8o1 gwcmzu0xy
29 Jun 11
Submission of Matters to a Vote of Security Holders
12:00am
8-K
s4s7swhiilaxh73w
23 Jun 11
Departure of Directors or Certain Officers
12:00am
8-K
eaixq
2 Jun 11
Departure of Directors or Certain Officers
12:00am
8-K
p1xq 6og7kkf
15 Feb 11
Departure of Directors or Certain Officers
12:00am
8-K
r970 yyrxkg8wszbbi
5 Jan 11
Bringing Total Award to Over $730,000
12:00am
8-K
ewb5min9hlgwull60kpx
22 Dec 10
Entry into a Material Definitive Agreement
12:00am
8-K
d4rxpq0o49 pc
8 Dec 10
Entry into a Material Definitive Agreement
12:00am
8-K
nnpsp1omo5ks2
1 Nov 10
Neogenix Oncology® Receives FDA Orphan Drug Status for Ensituximab (NPC-1C) for Treatment of Pancreatic Cancer
12:00am
8-K
deaneu
7 Oct 10
Other Events
12:00am
8-K
e9h0ds4drz8key2 hae
30 Sep 10
Other Events
12:00am
8-K
n7l8ejqsct 8q
23 Sep 10
Other Events
12:00am